No abstract

The aim of the work was to determine the clinical safety and immunogenicity of immunoadjuvant vaccines against inluenza (MonoGripol Plus and Grippol® Plus) in 182 pregnant women in the II and III trimesters of gestation , and further assessment of fetal conditions and infants of the irst 6 months of life. Results: It was shown that immunoadjuvant vaccines do not have a negative efect on the physiological course of pregnancy and the functional state of the fetoplacental complex. In the early postpartum period, the rates of physical and neuro-psychological development and the nature of feeding of children did not difer from the control group. In pregnant women vaccinated with Grippol® plus, the levels of seroprotection to strains of A/H1N1/v are 82.0%, A/H3N2/-88.0%, B-88.3% that measure the CPMP criteria and last more than a year . After birth, transplacental antibodies in children in protective values were observed in 52.3-68.9% of cases, did not difer from the control group, and disappear after 6 months. Respiratory infections during the irst 6 months of life of infants born from mothers vaccinated against inluenza registered in 1.8 times less frequently.Keywords: pregnant women, vaccine against inluenza, post-vaccination immunity.© 2017 The Author(s). Licensee InTech. This chapter is distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. IntroductionThe reports of Strategic Advisory Group of Experts (SAGE) on Immunization underscore that between 7 and 10% of all hospitalized patients with severe inluenza are women in the second and third trimester of pregnancy. The requirements of pregnant women with inluenza infection for providing medical care in an intensive care unit are 10 times that of other population groups diagnosed with inluenza [1][2][3][4].Vaccination of pregnant women using the subunit and split inluenza vaccines is routinely performed in a number of countries of Europe and America for over 20 years, and the vaccine eicacy reaches 70-85% [5,6]. Clinical studies have shown that vaccination of pregnant women using modern inactivated inluenza vaccines neither afect the course of pregnancy and fetal growth nor cause undesirable post-vaccination efects. It was found that vaccination of pregnant women using inactivated inluenza vaccines leads to 50-63% reduction of lurelated morbidity among infants up to 6 months of age [7,8].The WHO Global Advisory Commitee on Vaccine Safety indicates that inluenza vaccination is a non-alternative approach to safe and efective prevention of inluenza in pregnancy [1,9,10]. In Russia, the indications for vaccination of pregnant women using modern vaccines are deined within the National Immunization Program Schedule of Russian Federation (RF) (order of Ministry of Healthcare of Russian Federation №125n of 21 March 2014). Federal clinical guidelines "Inluenza vaccination of pregnan...